Cargando…

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Mostrar otras versiones (1)

Novel immunotherapy combination therapies have improved outcomes for patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of patients and recurrence can also occur. Little is known about the inter- and intra-tumor heterogeneity in cellular signaling networks within the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuming, Yuan, Long, Danilova, Ludmila, Mo, Guanglan, Zhu, Qingfeng, Deshpande, Atul, Bell, Alexander T.F., Elisseeff, Jennifer, Popel, Aleksander S., Anders, Robert A., Jaffee, Elizabeth M., Yarchoan, Mark, Fertig, Elana J., Kagohara, Luciane T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882076/ https://www.ncbi.nlm.nih.gov/pubmed/36712023 http://dx.doi.org/10.1101/2023.01.10.523481

Ejemplares similares

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial
por: Zhang, Shuming, et al.
Publicado: (2023)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
por: Ho, Won Jin, et al.
Publicado: (2020)

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response
por: Zhang, Shuming, et al.
Publicado: (2021)

Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
por: Shu, Daniel H., et al.
Publicado: (2023)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes
por: Fertig, Elana J., et al.
Publicado: (2015)

Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
por: Kagohara, Luciane T, et al.
Publicado: (2017)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
por: Sidiropoulos, Dimitrios N., et al.
Publicado: (2022)

Extracellular Vesicles Released by Tumor Endothelial Cells Spread Immunosuppressive and Transforming Signals Through Various Recipient Cells
por: Lopatina, Tatiana, et al.
Publicado: (2020)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
por: Davis-Marcisak, Emily F., et al.
Publicado: (2021)

Hybrid Modeling of Cell Signaling and Transcriptional Reprogramming and Its Application in C. elegans Development
por: Fertig, Elana J., et al.
Publicado: (2011)

Generating colorblind-friendly scatter plots for single-cell data
por: Guha, Tejas, et al.
Publicado: (2022)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis
por: Lee, Esak, et al.
Publicado: (2014)

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
por: Li, Keyu, et al.
Publicado: (2022)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance
por: Stein-O’Brien, Genevieve, et al.
Publicado: (2018)

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
por: Izumchenko, Evgeny, et al.
Publicado: (2015)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature
por: Zemankova, Anezka, et al.
Publicado: (2023)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
por: Ho, Won Jin, et al.
Publicado: (2021)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
por: Economides, Minas P., et al.
Publicado: (2020)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aga5kc5undqcni1ulqg7dorqq6